Elan drug Tysabri gets EC go-ahead

Elan Corporation plc and Biogen Idec today announced that they received approval from the European Commission to market Tysabri as a treatment for multiple sclerosis (MS).

Elan drug Tysabri gets EC go-ahead

Elan Corporation plc and Biogen Idec today announced that they received approval from the European Commission to market Tysabri as a treatment for multiple sclerosis (MS).

The drug delays the progression of the disability and reduces the frequency of relapses.

You have reached your article limit. Already a subscriber? Sign in

Continue reading for €5

Unlock unlimited access and exclusive benefits

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited